Business Context and Reporting Period
This Form 8-K was filed by RXi Pharmaceuticals Corporation (also referred to as Phio Pharmaceuticals Corp. in metadata) on April 9, 2012, reporting events occurring on April 3, 2012. The filing addresses a material definitive agreement regarding the company's financing arrangements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt totals, or liquidity ratios. The document focuses exclusively on the amendment of a securities purchase agreement and the extension of maturity dates for outstanding convertible promissory notes held by Galena Biopharma, Inc., Tang Capital Partners, LP, and RTW Investments, LLC.
Material Changes
- Agreement Amendment: On April 3, 2012, the company entered into an amendment to a securities purchase agreement originally dated September 24, 2011.
- Termination Date Extension: The date after which the agreement may be terminated by either party if closing has not occurred was extended to April 11, 2012.
- Note Maturity Extension: The maturity date of the outstanding convertible promissory notes held by the investors was extended to align with the new termination date.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general risks. The primary contingency noted is the potential termination of the securities purchase agreement if the closing does not occur by the new deadline of April 11, 2012.
Investor Verification Checklist
- Verify whether the closing of the securities purchase agreement occurred by the April 11, 2012 deadline.
- Confirm the current status and outstanding principal amount of the convertible promissory notes held by Galena Biopharma, Tang Capital Partners, and RTW Investments.
- Review subsequent filings to determine if the agreement was terminated or if further amendments were made after April 11, 2012.